Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

In an article published in The Lancet HIV, authors including Distinguished Professor Denis Nash and Professor Constantin Yiannoutsos aim to provide the most comprehensive estimates of pediatric ...

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...